84 related articles for article (PubMed ID: 30797493)
1. Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).
Andratschke N; Kraft J; Nieder C; Tay R; Califano R; Soffietti R; Guckenberger M
Lung Cancer; 2019 Mar; 129():63-71. PubMed ID: 30797493
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
Chamberlain MC; Baik CS; Gadi VK; Bhatia S; Chow LQ
Neuro Oncol; 2017 Jan; 19(1):i1-i24. PubMed ID: 28031389
[TBL] [Abstract][Full Text] [Related]
3. The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
Cerone MA; Mills TC; Sharpe R; McBride D; MacDonald M; MacMahon S; Mugalaasi H; Rehal P; Rettino A; Roberts H; Ross M; White DE; Peden J; Rawlinson J; Ho SN; Hollingsworth S; Popat S; Middleton G; Johnson P; Swanton C;
Br J Cancer; 2023 Jan; 128(2):161-164. PubMed ID: 36599918
[TBL] [Abstract][Full Text] [Related]
4. Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters.
Wang Y; Geller AE; Yan J
Signal Transduct Target Ther; 2023 May; 8(1):192. PubMed ID: 37156758
[No Abstract] [Full Text] [Related]
5. Management of brain metastases in non-small cell lung cancer without actionable driver mutations-the need to dive deeper in the right 'pool'.
Jablonska PA; Das A
Transl Lung Cancer Res; 2023 Oct; 12(10):1966-1971. PubMed ID: 38025807
[No Abstract] [Full Text] [Related]
6. Management of Brain Metastases in Non-Small-Cell Lung Cancer.
Ernani V; Stinchcombe TE
J Oncol Pract; 2019 Nov; 15(11):563-570. PubMed ID: 31715122
[TBL] [Abstract][Full Text] [Related]
7. Brain metastases in oncogene-driven non-small cell lung cancer.
Nishino M; Soejima K; Mitsudomi T
Transl Lung Cancer Res; 2019 Nov; 8(Suppl 3):S298-S307. PubMed ID: 31857953
[TBL] [Abstract][Full Text] [Related]
8. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.
Singh R; Lehrer EJ; Ko S; Peterson J; Lou Y; Porter AB; Kotecha R; Brown PD; Zaorsky NG; Trifiletti DM
Radiother Oncol; 2020 Mar; 144():165-179. PubMed ID: 31812932
[TBL] [Abstract][Full Text] [Related]
9. Management of CNS metastases in patients with EGFR mutation-positive NSCLC.
Shetty V; Babu S
Indian J Cancer; 2019 Nov; 56(Supplement):S31-S37. PubMed ID: 31793440
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatment of brain metastases in non-small cell lung cancer.
Page S; Milner-Watts C; Perna M; Janzic U; Vidal N; Kaudeer N; Ahmed M; McDonald F; Locke I; Minchom A; Bhosle J; Welsh L; O'Brien M
Eur J Cancer; 2020 Jun; 132():187-198. PubMed ID: 32380429
[TBL] [Abstract][Full Text] [Related]
11. Estimating Survival in Patients with Non-Small-Cell Lung Cancer and Brain Metastases: A Verification of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Li J; Jing W; Zhai X; Jia W; Zhu H; Yu J
Onco Targets Ther; 2021; 14():1623-1631. PubMed ID: 33688209
[TBL] [Abstract][Full Text] [Related]
12. Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?
Rudà R; Soffietti R
Neuro Oncol; 2020 Feb; 22(2):171-172. PubMed ID: 31858130
[No Abstract] [Full Text] [Related]
13. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges.
Chen ZY; Duan XT; Qiao SM; Zhu XX
Cancer Med; 2023 Jan; 12(2):995-1006. PubMed ID: 35986515
[TBL] [Abstract][Full Text] [Related]
15. Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy.
Lee J; Ahn MJ
Cancer Treat Rev; 2021 Nov; 100():102291. PubMed ID: 34587557
[TBL] [Abstract][Full Text] [Related]
16. How we treat octogenarians with brain metastases.
Nieder C; Andratschke NH; Grosu AL
Front Oncol; 2023; 13():1213122. PubMed ID: 37614511
[TBL] [Abstract][Full Text] [Related]
17. Factors Affecting 2-Year Survival in Patients With Non-Small Cell Lung Cancer Brain Metastases: Evidence from Indonesia's National Cancer Center, Jakarta, Indonesia.
Andriani R; Rosewitasari J; Hanif MA; Mulawarman A; Kurniawati SA; Fachri A
Clin Med Insights Oncol; 2023; 17():11795549231178172. PubMed ID: 37359276
[TBL] [Abstract][Full Text] [Related]
18. Predicting survival after radiosurgery in patients with lung cancer brain metastases using deep learning of radiomics and EGFR status.
Liao CY; Lee CC; Yang HC; Chen CJ; Chung WY; Wu HM; Guo WY; Liu RS; Lu CF
Phys Eng Sci Med; 2023 Jun; 46(2):585-596. PubMed ID: 36857023
[TBL] [Abstract][Full Text] [Related]
19. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review.
Nardone V; Romeo C; D'Ippolito E; Pastina P; D'Apolito M; Pirtoli L; Caraglia M; Mutti L; Bianco G; Falzea AC; Giannicola R; Giordano A; Tagliaferri P; Vinciguerra C; Desideri I; Loi M; Reginelli A; Cappabianca S; Tassone P; Correale P
Radiol Med; 2023 Mar; 128(3):316-329. PubMed ID: 36786970
[TBL] [Abstract][Full Text] [Related]
20. Improved Survival With Surgical Treatment of Primary Lung Lesions in Non-Small Cell Lung Cancer With Brain Metastases: A Propensity-Matched Analysis of Surveillance, Epidemiology, and End Results Database.
Wang Q; Li J; Liang X; Zhan Q
Front Oncol; 2022; 12():888999. PubMed ID: 35936705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
